The Crucial Problem of ASCVD: Can New Therapeutic Options Resolve it?

Saturday, 10/20 – 9:30am – 10:50am

Overview

Clinically evident atherosclerotic cardiovascular disease (ASCVD) is a leading cause of death and mortality in the US, and elevated serum LDL-C is a widely-recognized cardiovascular disease (CVD) risk factor. Since hypercholesterolemia is a major driver of ASCVD, lipid-lowering therapies (mainly statins) are the primary approach to lower low-density lipoprotein cholesterol (LDL-C). Unfortunately, intensive statin therapy lowers CVD risk by only ~50%, leaving many patients at excessively high residual CVD risk with no good options to reduce this risk.

The Crucial Problem of ASCVD: Can New Therapeutic Options Resolve It? will explore the residual CVD risk that ASCVD patients endure despite even intensive statin therapy. The education will also examine the possibility of additional CVD risk reduction by adding lipid-lowering therapies to statins, including the use of add-on therapies (ezetimibe and recent PCSK9 inhibitors) to improve clinical outcomes in this high-risk patient population.

Learning Objectives

  • Evaluate the extent of residual CVD risk to which ASCVD patients are exposed, and treat additional CVD risk elements as appropriate
  • Differentiate the clinical properties of new and emerging pharmacologic approaches to reduce LDL-C and lower CVD risk
  • Analyze the potential utility of new LDL-C lowering agents used in combination with statins to reduce CVD risk in patients who have ASCVD

Target Audience

The intended audiences for this initiative include family medicine practitioners, primary care providers, lipidologists, clinical cardiologists, internists, and other healthcare professionals tasked with refining and updating clinical decision-making practices and establishing partnerships with ASCVD patients to improve clinical outcomes.

Accreditation Information

AMA PRA Category 1 Credit: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please email: cme@bu.edu.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

AAFP: Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.

Steering Committee

Alan Brown, MD, FACC, FAHA, FNLA, FASPC
President, National Lipid Association
Director, Division of Cardiology
Advocate Heart Institute at Advocate Lutheran General Hospital
Co-Director, Advocate Medical Group
Naperville, IL

James A. Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA
Lipidology and Cardiovascular Disease Prevention
Clinical Assistant Professor of Medicine
NYU Medical School and NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
Immediate Past-President, National Lipid Association
New York, NY

Provider

Jointly provided by Boston University School of Medicine and Rockpointe.

       

Supporter

This activity is supported by educational funding provided by Amgen.

Long Beach 2018

Program Faculty

James A. Underberg, MD, MS, FNLA
Immediate Past-President, National Lipid Association
Clinical Assistant Professor of Medicine
NYU School of Medicine and
NYU Center for Prevention of Cardiovascular Disease
Director, Bellevue Hospital Lipid Clinic
New York, NY